Killing of escherichia coli by Crohn's disease monocyte-derived macrophages and its enhancement by hydroxychloroquine and Vitamin D

Inflammatory Bowel Diseases

Volumn 21, Issue 7, 2015, Pages 1499-1510

  Flanagan, Paul K ^a   Chiewchengchol, Direkrit ^a,b   Wright, Helen L ^a   Edwards, Steven W ^a   Alswied, Abdullah ^a   Satsangi, Jack ^c   Subramanian, Sreedhar ^d   Rhodes, Jonathan M ^a   Campbell, Barry J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

chemotaxis; ciprofloxacin; doxycycline; phagolysosomes

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CIPROFLOXACIN; DOXYCYCLINE; HYDROXYCHLOROQUINE; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; CYTOKINE; ENZYME INHIBITOR; VITAMIN;

ANIMAL CELL; ARTICLE; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; INTRACELLULAR KILLING; IRON METABOLISM; MACROPHAGE; MONOCYTE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; ADULT; ANIMAL; CELL CULTURE; COMBINATION DRUG THERAPY; ESCHERICHIA COLI INFECTIONS; FEMALE; IMMUNOLOGY; INNATE IMMUNITY; INTESTINE MUCOSA; ISOLATION AND PURIFICATION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ANIMALS; CELLS, CULTURED; CROHN DISEASE; CYTOKINES; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; IMMUNITY, INNATE; INTESTINAL MUCOSA; MACROPHAGES; MALE; MICE; MIDDLE AGED; PHAGOCYTOSIS; VITAMIN D; VITAMINS;

EID: 84932124273     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000387     Document Type: Article

References (62)

1. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut. 2013;62:1653-1664.
2. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146: 1489-1499.
3. Schwab C, Berry D, Rauch I, et al. Longitudinal study of murine microbiota activity and interactions with the host during acute inflammation and recovery. ISME J. 2014;8:1101-1114.
4. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology. 1998;115:1405-1413.
5. Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology. 2004;127:80-93.
6. Prorok-Hamon M, Friswell MK, Alswied A, et al. Colonic mucosaassociated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer. Gut. 2014;63:761-770.
7. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014;15:382-392.
8. Lapaquette P, Bringer MA, Darfeuille-Michaud A. Defects in autophagy favour adherent-invasive Escherichia coli persistence within macrophages leading to increased pro-inflammatory response. Cell Microbiol. 2012;14: 791-807.
9. Bringer MA, Glasser AL, Tung CH, et al. The Crohn's disease-Associated adherent-invasive Escherichia coli strain LF82 replicates in mature phagolysosomes within J774 macrophages. Cell Microbiol. 2006;8:471-484.
10. Meconi S, Vercellone A, Levillain F, et al. Adherent-invasive Escherichia coli isolated from Crohn's disease patients induce granulomas in vitro. Cell Microbiol. 2007;9:1252-1261.
11. Ryan P, Kelly RG, Lee G, et al. Bacterial DNA within granulomas of patients with Crohn's disease-detection by laser capture microdissection and PCR. Am J Gastroenterol. 2004;99:1539-1543.
12. Simpson KW, Dogan B, Rishniw M, et al. Adherent and invasive Escherichia coli is associated with granulomatous colitis in boxer dogs. Infect Immun. 2006;74:4778-4792.
13. Krauss E, Agaimy A, Neumann H, et al. Characterization of lymphoid follicles with red ring signs as first manifestation of early Crohn's disease by conventional histopathology and confocal laser endomicroscopy. Int J Clin Exp Pathol. 2012;5:411-421.
14. Roberts CL, Keita AV, Duncan SH, et al. Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut. 2010;59:1331-1339.
15. Chassaing B, Rolhion N, de Vallee A, et al. Crohn disease-Associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae. J Clin Invest. 2011;121:966-975.
16. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
17. Segal AW, Loewi G. Neutrophil dysfunction in Crohn's disease. Lancet. 1976;2:219-221.
18. Marks DJ, Harbord MW, MacAllister R, et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet. 2006;367: 668-678.
19. Smith AM, Rahman FZ, Hayee B, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med. 2009;206:1883-1897.
20. OMorain CO, Segal AA, Walker D, et al. Abnormalities of neutrophil function do not cause the migration defect in Crohn's disease. Gut. 1981; 22:817-822.
21. Rhodes JM, Jewell DP. Motility of neutrophils and monocytes in Crohn's disease and ulcerative colitis. Gut. 1983;24:73-77.
22. Wandall JH, Binder V. Leucocyte function in Crohn's disease. Studies on mobilisation using a quantitative skin window technique and on the function of circulating polymorphonuclear leucocytes in vitro. Gut. 1982;23: 173-180.
23. Mee AS, Szawatakowski M, Jewell DP. Monocytes in inflammatory bowel disease: phagocytosis and intracellular killing. J Clin Pathol. 1980;33:921-925.
24. Berger SB, Romero X, Ma C, et al. SLAM is a microbial sensor that regulates bacterial phagosome functions in macrophages. Nat Immunol. 2010;11:920-927.
25. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-Analysis. Am J Gastroenterol. 2011;106:661-673.
26. Dogan B, Scherl E, Bosworth B, et al. Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease. Inflamm Bowel Dis. 2013;19:141-150.
27. Subramanian S, Roberts CL, Hart CA, et al. Replication of colonic Crohn's disease mucosal Escherichia coli isolates within macrophages and their susceptibility to antibiotics. Antimicrob Agents Chemother. 2008;52:427-434.
28. Hoidal JR, Schmeling D, Peterson PK. Phagocytosis, bacterial killing, and metabolism by purified human lung phagocytes. J Infect Dis. 1981;144: 61-71.
29. Boulos A, Rolain JM, Raoult D. Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells. Antimicrob Agents Chemother. 2004;48:747-752.
30. Kersh GJ. Antimicrobial therapies for Q fever. Expert Rev Anti Infect Ther. 2013;11:1207-1214.
31. Lagier JC, Fenollar F, Lepidi H, et al. Treatment of classic Whipple's disease: from in vitro results to clinical outcome. J Antimicrob Chemother. 2014;69:219-227.
32. Hewison M. Vitamin D and immune function: an overview. Proc Nutr Soc. 2012;71:50-61.
33. Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease-A randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377-383.
34. Mpofu CM, Campbell BJ, Subramanian S, et al. Microbial mannan inhibits bacterial killing by macrophages: a possible pathogenic mechanism for Crohn's disease. Gastroenterology. 2007;133:1487-1498.
35. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006; 58:256-265.
36. Saravolatz L, Manzor O, Pawlak J, et al. Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae. Int J Antimicrob Agents. 2005;26:81-84.
37. Carmichael SJ, Charles B, Tett SE. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit. 2003;25:671-681.
38. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011; 364:248-254.
39. Fabri M, Stenger S, Shin DM, et al. Vitamin D is required for IFNgamma-mediated antimicrobial activity of human macrophages. Sci Transl Med. 2011;3:104ra102.
40. Di A, BrownME, Deriy LV, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol. 2006;8:933-944.
41. Byrd TF, Horwitz MA. Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens. J Clin Invest. 1991;88:351-357.
42. Van Limbergen J, Russell RK, Nimmo ER, et al. Autophagy gene ATG16L1 influences susceptibility and disease location but not childhood-onset in Crohn's disease in Northern Europe. Inflamm Bowel Dis. 2008;14:338-346.
43. Harbord MW, Marks DJ, Forbes A, et al. Impaired neutrophil chemotaxis in Crohn's disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor. Aliment Pharmacol Ther. 2006;24:651-660.
44. Sewell GW, Rahman FZ, Levine AP, et al. Defective tumor necrosis factor release from Crohn's disease macrophages in response to toll-like receptor activation: relationship to phenotype and genomewide association susceptibility loci. Inflamm Bowel Dis. 2012;18: 2120-2127.
45. van Heel DA, Hunt KA, King K, et al. Detection of muramyl dipeptidesensing pathway defects in patients with Crohn's disease. Inflamm Bowel Dis. 2006;12:598-605.
46. Van Dyke TE, Dowell VR Jr, Offenbacher S, et al. Potential role of microorganisms isolated from periodontal lesions in the pathogenesis of inflammatory bowel disease. Infect Immun. 1986;53:671-677.
47. DAmelio R, Pallone F, Le Moli S, et al. Humoral inhibition of neutrophil chemotaxis in Crohn's disease. Scand J Immunol. 1985;22:597-602.
48. Rhodes JM, Potter BJ, Brown DJ, et al. Serum inhibitors of leukocyte chemotaxis in Crohn's disease and ulcerative colitis. Gastroenterology. 1982;82:1327-1334.
49. Sadaghian Sadabad M, Regeling A, de Goffau MC, et al. The ATG16L1-T300A allele impairs clearance of pathosymbionts in the inflamed ileal mucosa of Crohn's disease patients. Gut. [published online ahead of print September 24, 2014]. doi: 10.1136/gutjnl-2014-307289.
50. Diacovich L, Gorvel JP. Bacterial manipulation of innate immunity to promote infection. Nat Rev Microbiol. 2010;8:117-128.
51. Flannagan RS, Cosio G, Grinstein S. Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nat Rev Microbiol. 2009;7:355-366.
52. Maurin M, Benoliel AM, Bongrand P, et al. Phagolysosomes of Coxiella burnetii-infected cell lines maintain an acidic pH during persistent infection. Infect Immun. 1992;60:5013-5016.
53. Winchell CG, Graham JG, Kurten RC, et al. Coxiella burnetii type IV secretion-dependent recruitment of macrophage autophagosomes. Infect Immun. 2014;82:2229-2238.
54. Maurin M, Benoliel AM, Bongrand P, et al. Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm. J Infect Dis. 1992;166:1097-1102.
55. Fenollar F, Lagier JC, Raoult D. Tropheryma whipplei and Whipple's disease. J Infect. 2014;69:103-112.
56. Louis E, Belaiche J. Hydroxychloroquine (Plaquenil) for recurrence prevention of Crohn's disease after curative surgery. Gastroenterol Clin Biol. 1995;19:233-234.
57. Arlet JB, Aouba A, Suarez F, et al. Efficiency of hydroxychloroquine in the treatment of granulomatous complications in chronic granulomatous disease. Eur J Gastroenterol Hepatol. 2008;20: 142-144.
58. Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003;110:1321-1326.
59. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov. 2012;11: 709-730.
60. Bhat M, Hickey AJ. Effect of chloroquine on phagolysosomal fusion in cultured Guinea pig alveolar macrophages: implications in drug delivery. AAPS PharmSci. 2000;2:E34.
61. Crowle AJ, May MH. Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3. Antimicrob Agents Chemother. 1990;34:2217-2222.
62. Chun RF, Liu PT, Modlin RL, et al. Impact of vitamin D on immune function: lessons learned from genome-wide analysis. Front Physiol. 2014;5:151.